
## Ana Elisa Lohmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7501145/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association of Obesity-Related Metabolic Disruptions With Cancer Risk and Outcome. Journal of Clinical Oncology, 2016, 34, 4249-4255.	1.6	77
2	A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. Breast, 2019, 48, 17-23.	2.2	73
3	Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis. Journal of the National Cancer Institute, 2021, 113, 1465-1475.	6.3	50
4	Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. Breast Cancer Research and Treatment, 2015, 150, 605-611.	2.5	19
5	Metabolic factors, anthropometric measures, diet, and physical activity in long-term breast cancer survivors: change from diagnosis and comparison to non-breast cancer controls. Breast Cancer Research and Treatment, 2017, 164, 451-460.	2.5	15
6	Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectrum, 2019, 3, pkz050.	2.9	15
7	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectrum, 2019, 3, pkz049.	2.9	11
8	Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer. JNCI Cancer Spectrum, 2018, 2, pky028.	2.9	10
9	Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. Breast Cancer Research and Treatment, 2017, 164, 371-378.	2.5	9
10	Normal Weight Adiposity and Postmenopausal Breast Cancer Risk. JAMA Oncology, 2019, 5, 150.	7.1	7
11	The effect of metformin on sex hormones in non-diabetic breast cancer patients in CCTG MA.32: A Phase III randomized adjuvant trial of metformin versus placebo in addition to standard therapy Journal of Clinical Oncology, 2019, 37, 529-529.	1.6	3
12	Hype versus Hope: Metformin and Vitamin D as Anticancer Agents. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e69-e74.	3.8	2
13	Novel Insights Into the Impact of Lifestyle-Based Weight Loss and Metformin on Obesity-Associated Biomarkers in Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 1161-1162.	6.3	2
14	Obesity and Breast Cancer: Expanding the Hypothesis Space. Journal of the National Cancer Institute, 2021, 113, 107-108.	6.3	2
15	Moving forward with obesity research in breast cancer. Breast, 2017, 32, 225-226.	2.2	1
16	Prognostic associations of 250H vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC) Journal of Clinical Oncology, 2014, 32, 504-504.	1.6	1
17	Association of obesity with breast cancer outcome in relation to cancer subtypes Journal of Clinical Oncology, 2019, 37, 11557-11557.	1.6	1
18	Modifiable metabolic markers c-peptide (C-PEP), highly sensitive c-reactive protein (hsCRP), leptin (LEP)] and lung cancer (LC) risk: A matched case-control study nested in the prostate, lung, colorectal and ovarian (PLCO) cancer screening study Journal of Clinical Oncology, 2015, 33, 1520-1520.	1.6	0

#	Article	IF	CITATIONS
19	The Futility of Futility Analyses in Adjuvant Trials in Hormone Receptor Positive Breast Cancer. Journal of the National Cancer Institute, 2022, , .	6.3	0